Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Carboplatin, Gemcitabine, and Thalidomide in Stage II/IIIA NSCLC
NCT00281827Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- May 2002
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide in non-small cell lung cancer (NSCLC), sponsored by Masonic Cancer Center. Started May 2002; status: terminated.
02
Drugs
thalidomide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00281827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00281827.